OBI Pharma, Inc.

NS Pharma Unveils Duchenne Heroes, a Program to Inspire and Amplify the Voices of People Living with Duchenne Muscular Dystrophy

Retrieved on: 
Tuesday, November 21, 2023
Dystrophin, Patient, Caregiver, Social media, OBI Pharma, Inc., Diagnosis, Duchenne muscular dystrophy, Tourism, Duchenne

Duchenne Heroes will share their insights on WeSpeakDuchenne.com, a new educational platform for families living with Duchenne

Key Points: 
  • Duchenne Heroes will share their insights on WeSpeakDuchenne.com, a new educational platform for families living with Duchenne
    PARAMUS, N.J., Nov. 21, 2023 /PRNewswire/ -- NS Pharma, Inc. ("NS Pharma") today announced the launch of Duchenne Heroes a program created to raise awareness and champion the voices of people affected by Duchenne muscular dystrophy (Duchenne).
  • Duchenne Heroes are individuals, caregivers and family members who hope to inspire others by sharing their personal experiences in navigating diagnosis and daily life with Duchenne.
  • "The Duchenne Heroes' insights and authentic experiences can inspire families who may be navigating a Duchenne diagnosis.
  • "It means a lot to our family to participate in the Duchenne Heroes program as we know how life-changing a Duchenne diagnosis can be," said Elizabeth Cojeen, member of the Duchenne Heroes program.

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

Retrieved on: 
Wednesday, November 1, 2023
Female, FDA, White Light Rock & Roll Review, Aes, Patent, Neuropathic pain, Wireless ambulatory ECG, U.S. Patent No. 1, Fast Track, Liver, MAD, Kidney, EPO, Volunteering, Priority review, Male, NSAIDS, Unified Patent Court, European Patent Office, PK, Accelerated approval (FDA), New Drug Application, Pain, Liver failure, Nonsteroidal anti-inflammatory drug, OBI Pharma, Inc., NDA, Fast track (FDA), Safety, Vital signs, Paracetamol, European Patent Convention, Plasma protein binding, Pharmaceutical industry, EU

NEW ORLEANS, Nov. 1, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company focused on developing innovative pain treatments, announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

Key Points: 
  • This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.
  • This patent, excluding possible patent term extensions, is expected to provide South Rampart with market exclusivity in the EPO member states until 2038, aligning with the U.S. Patent No.
  • On October 4, 2023, the U.S. FDA granted Fast Track designation to SRP-001 for acute pain.
  • The FDA Fast Track designation allows for more frequent interactions with the FDA, streamlining the clinical development plan and trial design to expedite drug approval.

Sunshine Biopharma Reports 2023 Second Quarter Results: Revenues Up 3,600%

Retrieved on: 
Friday, August 11, 2023
OBI Pharma, Inc., Pharmaceutical industry, Video game

MONTREAL, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 second quarter.

Key Points: 
  • MONTREAL, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its quarterly report for the 2023 second quarter.
  • The Company reported gross revenues of $5,560,865 for the quarter ended June 30, 2023, an increase of 3,600% over the same period in 2022.
  • In addition, the Company’s second quarter revenues of $5,560,865 represent a 13.6% increase over first quarter results.
  • “We are thrilled with our second quarter revenue results and look forward to continued quarter over quarter growth for the rest of 2023 and beyond,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Retrieved on: 
Tuesday, June 6, 2023
Tretinoin, Rosacea, Partnership, Philosophy, Dermatology, Acquisition, Patient, Physician, NESS, OBI Pharma, Inc., Sol–gel process, Benzoyl peroxide, Health, Acne, Fine chemical, Pharmaceutical industry, Medical device

TWYNEO and EPSOLAY are two innovative, large-market, dermatology products that were developed by Sol-Gel.

Key Points: 
  • TWYNEO and EPSOLAY are two innovative, large-market, dermatology products that were developed by Sol-Gel.
  • Both products recently launched in the U.S., and Searchlight is to commercialize them in Canada over a fifteen-year term that is renewable for subsequent five-year periods.
  • In addition, Sol-Gel will be entitled to royalty percentages of all Canadian net sales ranging from low-double-digits to high teens.
  • We look forward to collaborating with Searchlight to maximize the presence of our two unique drugs, TWYNEO and EPSOLAY, in Canada, a leading commercial territory.”

OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer

Retrieved on: 
Friday, June 2, 2023
OBI, University, Therapy, Medical community of ancient Rome, OBI Pharma, Inc., Bristol Myers Squibb, Cold, Fu Jen Catholic University, M.D, MD, Patient, BMS, Cold Spring Harbor Laboratory, Pharmaceutical industry

TAIPEI, Taiwan, June 02, 2023 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) | Effective immediately, the OBI Pharma Board of Directors have appointed Heidi Wang, Ph.D. as Chief Executive Officer, a position previously held by Chairman and CEO, Yun Yen, MD. “We are excited that Dr. Wang has been appointed CEO of OBI Pharma to bring strategic vision and lead the organization with our innovative cancer therapeutics pipeline, towards successful development and potentially regulatory approvals worldwide. Dr. Wang brings a wealth of global executive management, scientific knowledge, development, and regulatory experience during her ~30 years tenure at Bristol Myers Squibb company (BMS)™.

Key Points: 
  • Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally.
  • TAIPEI, Taiwan, June 02, 2023 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) | Effective immediately, the OBI Pharma Board of Directors have appointed Heidi Wang, Ph.D. as Chief Executive Officer, a position previously held by Chairman and CEO, Yun Yen, MD.
  • Dr. Wang brings a wealth of global executive management, scientific knowledge, development, and regulatory experience during her ~30 years tenure at Bristol Myers Squibb company (BMS)™.
  • “I am excited to contribute to the future direction and success of OBI Pharma as a potential leading cancer therapeutics biopharma company.

Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field

Retrieved on: 
Tuesday, May 16, 2023
Area studies, Partnership, Freedom, Astellas Pharma, Backbone, Sony, Enzyme, Type, Research, Cell, Solubility, Aggregation, Patient, OBI Pharma, Inc., Drug discovery, Conjugation, Biology, ADC, DAR, Antibody-drug conjugate, TSE, Fine chemical, Pharmaceutical industry

TOKYO, May 16, 2023 /PRNewswire/ -- Sony Corporation (President and CEO: Kimio Maki, "Sony") and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC)*1 platform in oncology based on Sony's unique polymeric material, "KIRAVIATM*2 Backbone*3." ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells. The technology to create linkers which conjugate antibodies and drugs is considered to be a key to the development of a better-performing ADC. This collaborative research leverages the flexibility in design and resulting properties such as high capacity and solubility of KIRAVIA Backbone as a linker of ADC, to effectively deliver anti-cancer drugs to targeted cells in a stable manner, aiming to further enhance therapeutic efficacy by achieving high Drug-to-Antibody Ratio (DAR), etc.

Key Points: 
  • " ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells.
  • The technology to create linkers which conjugate antibodies and drugs is considered to be a key to the development of a better-performing ADC.
  • The two companies jointly began exploratory research of new linker technology aimed at creating a new ADC platform in July 2022, and the expected profile was obtained in feasibility studies using human cancer cells.
  • Under this agreement, Sony and Astellas will jointly develop and optimize a new ADC platform using the KIRAVIA Backbone as a linker.

Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field

Retrieved on: 
Tuesday, May 16, 2023
Area studies, Partnership, Freedom, Astellas Pharma, Backbone, Sony, Enzyme, Type, Research, Cell, Solubility, Aggregation, Patient, OBI Pharma, Inc., Drug discovery, Conjugation, Biology, ADC, DAR, Antibody-drug conjugate, TSE, Fine chemical, Pharmaceutical industry

TOKYO, May 16, 2023 /PRNewswire/ -- Sony Corporation (President and CEO: Kimio Maki, "Sony") and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC)*1 platform in oncology based on Sony's unique polymeric material, "KIRAVIA™*2 Backbone*3." ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells. The technology to create linkers which conjugates antibodies and drugs, is considered to be a key to development of a better-performing ADC. This collaborative research leverages the flexibility in design and resulting properties such as high capacity and solubility of KIRAVIA Backbone as a linker of ADC, to effectively deliver anti-cancer drugs to targeted cells in a stable manner, aiming to further enhance therapeutic efficacy by achieving high Drug-to-Antibody Ratio (DAR) etc.

Key Points: 
  • " ADC is expected to selectively deliver anti-cancer drugs to target cells, thereby increasing efficacy and reducing side effects caused by anti-cancer drugs attacking normal cells.
  • The technology to create linkers which conjugates antibodies and drugs, is considered to be a key to development of a better-performing ADC.
  • The two companies jointly began exploratory research of new linker technology aimed at creating a new ADC platform in July 2022, and the expected profile was obtained in feasibility studies using human cancer cells.
  • Under this agreement, Sony and Astellas will jointly develop and optimize a new ADC platform using the KIRAVIA Backbone as a linker.

Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

Retrieved on: 
Thursday, May 11, 2023
Treasury, University, Jewish General Hospital, SEC Rule 144A, SARS-CoV-2, Coronavirus, COVID-19, McGill University Health Centre, Research, University of Illinois Chicago, Sunlight, Report, General Hospital, End-user license agreement, License, University of Illinois Urbana-Champaign, OBI Pharma, Inc., CFO, Growth, IND, Pharmaceutical industry

The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a generic pharmaceuticals company that Sunshine Biopharma acquired in October 2022.

Key Points: 
  • The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a generic pharmaceuticals company that Sunshine Biopharma acquired in October 2022.
  • The following are 2023 first quarter highlights:
    On January 19, 2023, Sunshine Biopharma announced a stock repurchase program of up to $2 million under SEC Rule 10B-18.
  • On February 10, 2023, Sunshine Biopharma entered into a research agreement with the Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada.
  • On February 28, 2023, Sunshine Biopharma entered into an exclusive worldwide License Agreement with the University of Arizona.

IntelGenx Announces Organizational Changes to Support Global Growth Strategy

Retrieved on: 
Thursday, April 13, 2023
Pillar, Regulation of tobacco by the U.S. Food and Drug Administration, Senior, Intellectual property, MBA, Doctor of Philosophy, Retirement, OBI Pharma, Inc., Corporate development, General counsel, Raymond, GSK plc, Alexion Pharmaceuticals, PDUFA, TSX, Knowledge, Growth, Rare, FDA, GSK, Biotechnology, CMO, Prescription Drug User Fee Act, Raymond Chabot Grant Thornton, Rizatriptan, Corporate services, WSBG, NDA, AstraZeneca, CDMO, OTC, CPA, Pleasure, ANDA, Market for corporate control, Food, Management

SAINT LAURENT, Quebec, April 13, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced various changes to its management team.

Key Points: 
  • SAINT LAURENT, Quebec, April 13, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced various changes to its management team.
  • IntelGenx is looking forward to the commercialization of both product candidates, pending positive FDA decisions, as soon as is practicable.
  • "Assuming positive FDA decisions in the near-future, we will be entering a stage of anticipated rapid growth," concluded Dr. Zerbe.
  • "Importantly, with these management changes following my retirement as CEO, we have a leadership team that is optimally structured to support both our current business and the successful execution of our long-term strategy.”

PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets

Retrieved on: 
Wednesday, April 12, 2023
Bankruptcy, Chapter 11, Title 11, United States Code, APA, United States bankruptcy court, Electric Bond and Share Company v. Securities and Exchange Commission, OBI Pharma, Inc., Security (finance), FDA, Cryptocurrency, Sale

The Company today announced that it entered into a stalking horse asset purchase agreement (the “APA”) with PLx Acquisition Company, LLC, a wholly-owned subsidiary of Greenwood Brands, LLC (“Buyer”), to acquire substantially all of the Company’s assets (the “Sale”).

Key Points: 
  • The Company today announced that it entered into a stalking horse asset purchase agreement (the “APA”) with PLx Acquisition Company, LLC, a wholly-owned subsidiary of Greenwood Brands, LLC (“Buyer”), to acquire substantially all of the Company’s assets (the “Sale”).
  • The Sale would also be subject to higher and better offers the Company may receive during an auction process.
  • The APA is subject to certain customary closing conditions, including certain orders being entered by the Bankruptcy Court.
  • The above description of the APA and the transactions contemplated, including the Sale, does not purport to be complete.